- Home
- MATV vs PROK Comparison
MATV vs PROK Comparison
Compare MATV & PROK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MATV | PROK |
|---|---|---|
| Founded | 1995 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Paper | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 440.9M | 359.4M |
| IPO Year | 1996 | 2021 |
Fundamental Metrics
Financial Performance| Metric | MATV | PROK |
|---|---|---|
| Price | $12.25 | $1.60 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $6.25 |
| AVG Volume (30 Days) | 425.4K | ★ 1.3M |
| Earning Date | 11-04-2026 | 11-09-2026 |
| Dividend Yield | ★ 3.30% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $893,000.00 |
| Revenue This Year | $1.75 | N/A |
| Revenue Next Year | $3.32 | $7.83 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 1075.00 |
| 52 Week Low | $7.07 | $1.30 |
| 52 Week High | $15.48 | $3.48 |
Technical Indicators
Market Signals| Indicator | MATV | PROK |
|---|---|---|
| Relative Strength Index (RSI) | 57.20 | 43.45 |
| Support Level | $11.76 | $1.55 |
| Resistance Level | $12.74 | $2.01 |
| Average True Range (ATR) | 0.37 | 0.12 |
| MACD | -0.06 | -0.03 |
| Stochastic Oscillator | 71.21 | 12.50 |
Price Performance
Historical ComparisonAbout MATV Mativ Holdings Inc.
Mativ Holdings Inc is a leader in specialty materials, solving its customers' complex challenges by engineering bold, inventive solutions that connect, protect, and purify the world. The company operates in two segments, namely Filtration & advanced Materials, focused on filtration media and components, developed films, coating and converting solutions, and extruded mesh products, and (2) Sustainable & Adhesive Solutions (SAS), focused on tapes, labels, liners, specialty paper, packaging, and healthcare solutions.
About PROK ProKidney Corp.
ProKidney Corp is a clinical-stage biotechnology company pioneering the development of a first-in-class, autologous cell therapy that is intended to preserve kidney function in patients with advance chronic kidney disease (CKD) and diabetes. Its product candidate, REACT (Renal Autologous Cell Therapy), is a disease-modifying cell therapy made from a patient's renal cells. REACT has the potential to slow and stabilize the progression of chronic kidney disease. The company's pipeline consists of the development program for severe diabetic kidney disease.